Australia Jobs Growth Strengthens Rate Hike Outlook 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Gold Prices Rise Above $4,000 as Inflation Data and Weaker Dollar Boost Demand 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
Australian Household Spending Rebounds Strongly in May as Travel and Dining Drive Consumer Growth 
Oil Prices Rebound as Strait of Hormuz Tensions Return After Ship Attack Near Oman 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Merck & Co., Inc. was first revealed to be in the last phase of talks to acquire Prometheus Biosciences Inc., a California-based biotech company. Now, the deal was already confirmed by the company.
Reuters previously reported that sources said the acquisition could be announced on Sunday, April 16. At that time, they were cautious about sharing any other details because there was still a possibility for the talks to fall apart.
But indeed, the deal pushed through, and Merck & Co. has officially acquired Prometheus Biosciences, which specializes in the development and production of therapeutic products for the treatment of immune-mediated diseases. The company’s market capitalization was said to be $5.42 billion at Friday’s closing.
In any case, Merck & Co. was said to be hunting for deals to shield the company from eventual revenue loss because its Keytruda cancer immunotherapy patents are set to expire at the end of the decade. It has also released its 2023 earnings estimates that showed a huge decline in sales of its COVID-19 antiviral treatment.
“At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportunities where compelling science and value creation align,” Merck & Co. chairman and chief executive officer, Robert M. Davis, said in a press release. “The agreement with Prometheus will accelerate our growing presence in immunology where there remains a substantial unmet patient need.”
He added that its acquisition of Prometheus Biosciences “adds diversity to our overall portfolio and is an important building block as we strengthen the sustainable innovation engine that will drive our growth well into the next decade.”
Mark McKenna, the chairman and CEO of Prometheus Biosciences, also commented, “Prometheus was established to revolutionize the treatment of immune-mediated diseases through the application of a powerful precision medicine approach, and this agreement with Merck, a leader in biopharmaceutical research and development, allows Prometheus to maximize the potential for PRA023 while continuing to apply our technology and expertise to fuel further discoveries to address the needs of patients with immune disorders.”
